Cardiovascular complications in autosomal dominant polycystic kidney disease

Current Hypertension Reviews

Volumn 9, Issue 1, 2013, Pages 2-11

  Ecder, Tevfik ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Antihypertensive therapy; Autosomal dominant polycystic kidney disease; Cardiovascular complications; Hypertension; Left ventricular hypertrophy; Renin angiotensin aldosterone system

Indexed keywords

ENALAPRIL; LISINOPRIL; POLYCYSTIN 1; POLYCYSTIN 2; PRAVASTATIN; RAMIPRIL; TELMISARTAN;

ANEURYSM; ARTERIAL STIFFNESS; ARTERIAL WALL THICKNESS; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CORONARY FLOW RESERVE; DISEASE ASSOCIATION; DISEASE COURSE; EARLY DIAGNOSIS; GLOMERULUS FILTRATION RATE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; INSULIN RESISTANCE; KIDNEY FUNCTION; KIDNEY POLYCYSTIC DISEASE; MICROALBUMINURIA; MULTICENTER STUDY (TOPIC); OBESITY; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; VALVULAR HEART DISEASE; VASCULAR RESISTANCE;

ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; HUMANS; HYPERTENSION; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; RENIN-ANGIOTENSIN SYSTEM;

EID: 84875321690     PISSN: 15734021     EISSN: 18756506     Source Type: Journal    
DOI: 10.2174/1573402111309010002     Document Type: Article

References (113)

1. Ecder T, Fich-Brosnahan GM, Schrier RW. Polycystic kidney disease. In: Schrier RW, Ed. Diseases of the kidney and urinary tract. Philadelphia Williams & Wilkins, 2007; 502-539.
2. Grantham JJ. Clinical practice: autosomal dominant polycystic kidney disease. N Engl J Med 2008; 359: 1477-1485.
3. Fick GM, Johnson AM, Hammond WS, Gabow PA. Causes of death in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 1995; 5: 2048-2056.
4. Perrone RD, Ruthazer R, Terrin NC. Survival after end-stage renal disease in autosomal dominant polycystic kidney disease: contribution of extrarenal complications to mortality. Am J Kidney Dis 2001; 38: 777-784.
5. Chapman AB, Schrier RW. Pathogenesis of hypertension in autosomal dominant polycystic kidney disease. Semin Nephrol 1991; 11: 653-660.
6. Ecder T, Schrier RW. Hypertension in autosomal-dominant polycystic kidney disease: early occurrence and unique aspects. J Am Soc Nephrol 2001; 12: 194-200.
7. Gabow PA, Johnson AM, Kaehny WD, et al. Factors affecting the progression of renal disease in autosomal-dominant polycystic kidney disease. Kidney Int 1992; 41: 1311-1319.
8. Chapman AB, Johnson AM, Rainguet S, Hossack K, Gabow P, Schrier RW. Left ventricular hypertrophy in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 1997; 8: 1292-1297.
9. Kelleher CL, McFann KK, Johnson AM, Schrier RW. Characteristics of hypertension in young adults with autosomal dominant polycystic kidney disease compared with the general U.S. population. Am J Hypertens 2004; 17: 1029-1034.
10. Schrier RW, Johnson AM, McFann KK, Chapman AB. The role of parental hypertension in the frequency and age of diagnosis of hypertension in offspring with autosomal-dominant polycystic kidney disease. Kidney Int 2003; 64: 1792-1799.
11. Sedman A, Bell P, Manco-Johnson M, et al. Autosomal dominant polycystic kidney disease in childhood: a longitudinal study. Kidney Int 1987; 31: 1000-1005.
12. Fick GM, Duley IT, Johnson AM, Strain JD, Manco-Johnson ML, Gabow PA. The spectrum of autosomal dominant polycystic kidney disease in children. J Am Soc Nephrol 1994; 4: 1654-1660.
13. Ivy DD, Shaffer EM, Johnson AM, Kimberling WJ, Dobin A, Gabow PA. Cardiovascular abnormalities in children with autosomal dominant polycystic kidney disease. J Am Soc Nephrol 1995; 5: 2032-206.
14. Shamshirsaz A, Bekheirnia RM, Kamgar M, et al. Autosomal-dominant polycystic kidney disease in infancy and childhood: progression and outcome. Kidney Int 2005; 68: 2218-2224.
15. Gabow PA, Chapman AB, Johnson AM, et al. Renal structure and hypertension in autosomal dominant polycystic kidney disease. Kidney Int 1990; 38: 1177-1180.
16. Graham PC, Lindop GBM. The anatomy of the renin-secreting cell in adult polycystic kidney disease. Kidney Int 1988; 33: 1084-1090.
17. Torres VE, Donovan KA, Scicli G, et al. Synthesis of renin by tubulocystic epithelium in autosomal-dominant polycystic kidney disease. Kidney Int 1992; 42: 364-373.
18. Loghman-Adham M, Soto CE, Inagami T, Cassis L. The intrarenal renin-angiotensin system in autosomal dominant polycystic kidney disease. Am J Physiol Renal Physiol 2004; 287: F775-F788.
19. Chapman AB, Johnson A, Gabow PA, Schrier RW. The renin- angiotensin-aldosterone system and autosomal dominant polycystic kidney disease. N Engl J Med 1990; 323: 1091-1096.
20. Torres VE, Wilson DM, Burnett JC, Johnson CM, Offord KP: Effect of inhibition of converting enzyme on renal hemodynamics and sodium management in polycystic kidney disease. Mayo Clin Proc 1991; 66: 1010-1017.
21. Watson ML, Macnicol AM, Allan PL, Wright AF. Effects of angiotensin converting enzyme inhibition in adult polycystic kidney disease. Kidney Int 1991; 41: 206-210.
22. Doulton TW, Saggar-Malik AK, He FJ, et al. The effect of sodium and angiotensin-converting enzyme inhibition on the classic circulating renin-angiotensin system in autosomal-dominant polycystic kidney disease patients. J Hypertens 2006; 24: 939-945.
23. Harrap SB, Davies DL, Macnicol AM, et al. Renal, cardiovascular and hormonal characteristics of young adults with autosomal dominant polycystic kidney disease. Kidney Int 1991; 40: 501-508.
24. Barrett BJ, Foley R, Morgan J, Hefferton D, Parfrey P. Differences in hormonal and renal vascular responses between normotensive patients with autosomal dominant polycystic kidney disease and unaffected family members. Kidney Int 1994; 46: 1118-1123.
25. Torres VE, Wilson DM, Offord K P, Burnett JC, Romero JC. Natriuretic response to volume expansion in polycystic kidney disease. Mayo Clin Proc 1989; 64: 509-515.
26. Klein IHHT, Ligtenberg G, Oey PL, Koomans HA, Blankestijn PJ. Sympathetic activity is increased in polycystic kidney disease and is associated with hypertension. J Am Soc Nephrol 2001; 12: 2427-2433.
27. Hocher B, Zart R, Schwarz A, et al. Renal endothelin system in polycystic kidney disease. J Am Soc Nephrol 1998; 9: 1169-1177.
28. Munemura C, Uemasu J, Kawasaki H. Epidermal growth factor and endothelin in cyst fluid from autosomal dominant polycystic kidney disease cases: possible evidence of heterogeneity in cystogenesis. Am J Kidney Dis 1994; 24: 561-568.
29. Giusti R, Neri M, Angelini D, et al. Plasma concentration of endothelin and arterial pressure in patients with ADPKD. Contrib Nephrol 1995; 115: 118-121.
30. Wang D, Iversen J, Strandgaard S. Endothelium-dependent relaxation of small resistance vessels is impaired in patients with autosomal dominant polycystic kidney disease. J Am Soc Nephrol 2000; 11: 1371-1376.
31. Wang D, Iversen J, Wilcox CS, Strandgaard S. Endothelial dysfunction and reduced nitric oxide in resistance arteries in autosomal dominant polycystic kidney disease. Kidney Int 2003; 64: 1381-1388.
32. Al-Nimri MA, Komers R, Oyama TT, Subramanya AR, Lindsley JN, Anderson S. Endothelium-derived vasoactive mediators in polycystic kidney disease. Kidney Int 2003; 63: 1776-1784.
33. Merta M, Reiterova J, Rysava R, et al. Role of endothelin and nitric oxide in the pathogenesis of arterial hypertension in autosomal dominant polycystic kidney disease. Physiol Res 2003; 52: 433-437.
34. Wang D, Strandgaard S, Borresen ML, et al. Asymmetric dimethylarginine and lipid peroxidation products in early autosomal dominant polycystic kidney disease. Am J Kidney Dis 2008; 51: 184-191.
35. Menon V, Rudym D, Chandra P, Miskulin D, Perrone R, Sarnak M. Inflammation, oxidative stress, and insulin resistance in polycystic kidney disease. Clin J Am Soc Nephrol 2011; 6: 7-13.
36. Kocaman O, Oflaz H, Yekeler E, et al. Endothelial dysfunction and increased carotid intima-media thickness in patients with autosomal dominant polycystic kidney disease. Am J Kidney Dis 2004; 43: 854-860.
37. Rong S, Jin X, Ye C, Chen J, Mei C. Carotid vascular remodeling in patients with autosomal dominant polycystic kidney disease. Nephrology 2009; 14: 113-117
38. Turkmen K, Oflaz H, Uslu B, et al. Coronary flow velocity reserve and carotid intima media thickness in patients with autosomal dominant polycystic kidney disease: from impaired tubules to impaired carotid and coronary arteries. Clin J Am Soc Nephrol 2008; 3: 986-991.
39. Alisir S, Turkmen K, Alpay N, et al. Improvement of coronary flow velocity reserve with telmisartan in patients with autosomal-dominant polycystic kidney disease. Southern Medical Journal 2010; 103: 409-413.
40. Borresen ML, Wang D, Strandgaard S. Pulse wave reflection is amplified in normotensive patients with autosomal-dominant polycystic kidney disease and normal renal function. Am J Nephrol 2007; 27: 240-246.
41. Griffin MD, Torres VE, Grande J P, Kumar R. Vascular expression of polycystin. J Am Soc Nephrol 1997; 8: 616-626.
42. Torres VE, Cai Y, Chen X, et al. Vascular expression of polycystin-2. J Am Soc Nephrol 2001; 12: 1-9.
43. Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 1991; 114: 345-352.
44. Zeier M, Geberth S, Schmidt KG, Mandelbaum A, Ritz E. Elevated blood pressure profile and left ventricular mass in children and young adults with autosomal dominant polycystic kidney disease. J Am Soc Nephrol 1993; 3: 1451-1457.
45. Bardaji A, Martinez-Vea A, Valero A, et al. Cardiac involvement in autosomal dominant polycystic kidney disease: a hypertensive heart disease. Clin Nephrol 2002; 56: 211-220.
46. Cadnapaphornchai MA, McFann KK, Strain JD, Masoumi A, Schrier RW. Increased left ventricular mass in children with autosomal dominant polycystic kidney disease and borderline hypertension. Kidney Int 2008; 74: 1192-1196.
47. Saggar-Malik A, Missouris CG, Gill JS, Singer DRJ, Markandu ND, MacGregor GA. Left ventricular mass in normotensive subjects with autosomal dominant polycystic kidney disease. BMJ 1994; 309: 1617-1618.
48. Bardaji A, Martinez-Vea AM, Gutierrez C, Ridao C, Richart C, Oliver JA. Left ventricular mass and diastolic function in normotensive young adults with autosomal dominant polycystic kidney disease. Am J Kidney Dis 1998; 32: 970-975.
49. Oflaz H, Alisir S, Buyukaydin B, et al. Biventricular diastolic dysfunction in patients with autosomal dominant polycystic kidney disease. Kidney Int 2005; 68: 2244-2249
50. Verdecchia P, Schillaci G, Guerrieri M, et al. Circadian blood pressure changes and left ventricular hypertrophy in essential hypertension. Circulation 1990; 81: 528-536.
51. Li Kam Wa TC, Macnicol AM, Watson ML. Ambulatory blood pressure in hypertensive patients with autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 1997; 12: 2075-2080.
52. Valero FA, Martinez-Vea A, Bardaji A, et al. Ambulatory blood pressure and left ventricular mass in normotensive patients with autosomal dominant polycystic kidney disease. J Am Soc Nephrol 1999; 10: 1020-1026.
53. Turgut F, Oflaz H, Namli S, et al. Ambulatory blood pressure and endothelial dysfunction in patients with autosomal dominant polycystic kidney disease. Ren Fail 2007; 29: 979-984.
54. Martinez-Vea A, Bardaji A, Gutierrez C, et al. Exercise blood pressure, cardiac structure, and diastolic function in young normotensive patients with polycystic kidney disease: a prehypertensive state. Am J Kidney Dis 2004; 44: 216-223.
55. Almeida EAF, Oliveira EI, Lopes JA, Almeida AG, Prata MM. Tissue Doppler imaging in the evaluation of left ventricular function in young adults with autosomal dominant polycystic kidney disease. Am J Kidney Dis 2006; 47: 587-592.
56. Phillips RA, Krakoff LR, Dunaif A, Finegood DT, Gorlin R, Shimabukuro S. Relation among left ventricular mass, insulin resistance, and blood pressure in nonobese subjects. J Clin Endocrinol Metab 1998; 83: 4284-4288
57. Ohya Y, Abe I, Fujii K, et al. Hyperinsulinemia and left ventricular geometry in a work-site population in Japan. Hypertension 1996; 27: 729-734.
58. Vareesangthip K, Tong P, Wilkinson R, Thomas TH. Insulin resistance in adult polycystic kidney disease. Kidney Int 1997; 52: 503-508.
59. Lumiaho A, Pihlajamaki J, Hartikainen J, et al. Insulin resistance is related to left ventricular hypertrophy in patients with polycystic kidney disease type 1. Am J Kidney Dis 2003; 41: 1219-1224.
60. Rocchini A P, Moorehead C, DeRemer S, Goodfriend TL, Ball DL. Hyperinsulinemia and the aldosterone and pressor responses to angiotensin II. Hypertension 1990; 15: 861-866.
61. Lembo G, Napoli R, Capaldo B, et al. Abnormal sympathetic overactivity evoked by insulin in the skeletal muscle of patients with essential hypertension. J Clin Invest 1992; 90: 24-29.
62. Gharavi AG, Lipkowitz MS, Diamond JA, Jhang JS, Phillips RA. Deletion polymorphism of the angiotensin-converting enzyme gene is independently associated with left ventricular mass and geometric remodeling in systemic hypertension. Am J Cardiol 1996; 77: 1315-1319.
63. Estacio RO, Jeffers BW, Havranek E P, Krick D, Raynolds M, Schrier RW. Deletion polymorphism of the angiotensin-converting enzyme gene is associated with an increase in left ventricular mass in men with type 2 diabetes mellitus. Am J Hypertens 1999; 12: 637-642.
64. Baboolal K, Ravine D, Daniels J, et al. Association of the angiotensin I converting enzyme gene deletion polymorphism with early onset of ESRF in PKD1 adult polycystic kidney disease. Kidney Int 1997; 52: 607-613.
65. Perez-Oller L, Torra R, Badenas C, Mila M, Darnell A. Influence of the ACE gene polymorphism in the progression of renal failure in autosomal dominant polycystic kidney disease. Am J Kidney Dis 1999; 34: 273-278.
66. van Dijk MA, Breuning MH, Peters DJM, Chang PC. The ACE insertion/deletion polymorphism has no influence on progression of renal function loss in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 2000; 15: 836-839.
67. Schiavello T, Burke V, Bogdanova N, et al. Angiotensin-converting enzyme activity and the ACE Alu polymorphism in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 2001; 16: 2323-2327.
68. Ecder T, McFann KK, Raynolds MV, Schrier RW. No effect of angiotensin converting enzyme gene polymorphism on disease progression and left ventricular hypertrophy in autosomal dominant polycystic kidney disease. Am J Nephrol 2003; 23: 466-470.
69. Chapman AB, Rubinstein D, Hughes R, et al. Intracranial aneurysms in autosomal dominant polycystic kidney disease. N Engl J Med 1992; 327: 916-920.
70. Ruggieri PM, Poulos N, Masaryk TJ, et al. Occult intracranial aneurysms in polycystic kidney disease: screening with MR angiography. Radiology 1994; 191: 33-39.
71. Graf S, Schischma A, Eberhardt KE, Istel R, Stiasny B, Schulze BD. Intracranial aneurysms and dolichoectasia in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 2002; 17: 819-823.
72. Brisman JL, Song JK, Newell D W. Cerebral aneurysms. N Engl J Med 2006; 355: 928-939.
73. Schievink WI, Prendergast V, Zabramski JM. Rupture of a previously documented small asymptomatic intracranial aneurysm in a patient with autosomal dominant polycystic kidney disease. Neurosurgery 1998; 89: 479-482.
74. Hadimeri H, Lamm C, Nyberg G. Coronary aneurysms in patients with autosomal dominant polycystic kidney disease. J Am Soc Nephrol 1998; 9: 837-841.
75. Kanagasundaram NS, Perry E P, Turney JH. Aneurysm of the splenic artery in a patient with autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 1999; 14: 183-184.
76. Torra R, Nicolau C, Badenas C, et al. Abdominal aortic aneurysms and autosomal dominant polycystic kidney disease. J Am Soc Nephrol 1996; 7: 2483-2486.
77. Belz MM, Hughes RL, Kaehny WD, et al. Familial clustering of ruptured intracranial aneurysms in autosomal dominant polycystic kidney disease. Am J Kidney Dis 2001; 38: 770-776.
78. Belz MM, Fick-Brosnahan GM, Hughes RL, et al. Recurrence of intracranial aneurysms in autosomal-dominant polycystic kidney disease. Kidney Int 2003; 63: 1824-1830.
79. Schrier RW. Optimal care of autosomal dominant polycystic kidney disease patients. Nephrology 2006; 11: 124-130.
80. Schrier RW, Belz MM, Johnson AM, et al. Repeat imaging for intracranial aneurysms in patients with autosomal dominant polycystic kidney disease with initially negative studies: a prospective ten year follow-up. J Am Soc Nephrol 2004; 15: 1023-1028.
81. Leier C V, Baker PB, Kilman JW, Wooley CF. Cardiovascular abnormalities associated with adult polycystic kidney disease. Ann Intern Med 1984; 100: 683-688.
82. Hossack KF, Leddy CL, Johnson AM, Schrier RW, Gabow PA. Echocardiographic findings in autosomal dominant polycystic kidney disease. N Engl J Med 1988; 319: 907-912.
83. Timio M, Pede MS, Verdura C, Lolli S. The spectrum of cardiovascular abnormalities in autosomal dominant polycystic kidney disease: a 10-year follow-up in a five-generation kindred. Clin Nephrol 1992; 37: 245-251.
84. Lumiaho A, Ikaheimo R, Miettinen R, et al. Mitral valve prolapse and mitral regurgitation are common in patients with polycystic kidney disease type 1. Am J Kidney Dis 2001; 38: 1208-1216.
85. Klahr S, Breyer JA, Beck GJ, et al. Dietary protein restriction, blood pressure control, and the progression of polycystic kidney disease. J Am Soc Nephrol 1995; 5: 2037-2047.
86. Maschio G, Alberti D, Janin G, et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 1996; 334: 939-945.
87. Ecder T, Chapman AB, Brosnahan GM, Edelstein CL, Johnson AM, Schrier RW. Effect of antihypertensive therapy on renal function and urinary albumin excretion in hypertensive patients with autosomal dominant polycystic kidney disease. Am J Kidney Dis 2000; 35: 427-432.
88. Chapman AB, Johnson AM, Gabow PA, Schrier RW. Overt proteinuria and microalbuminuria in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 1994; 5: 1349-1354.
89. van Dijk MA, Breuning MH, Duiser R, van Es LA, Westendorp RGJ. No effect of enalapril on progression in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 2003; 18: 2314-2320.
90. Zeltner R, Poliak R, Stiasny B, Schmieder RE, Schulze BD. Renal and cardiac effects of antihypertensive treatment with ramipril vs metoprolol in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 2008; 23: 573-579.
91. Ecder T, Edelstein CL, Fick-Brosnahan GM, et al. Diuretics versus angiotensin converting enzyme inhibitors in autosomal dominant polycystic kidney disease. Am J Nephrol 2001; 21: 98-103.
92. Nutahara K, Higashihara E, Horie S, et al. Calcium channel blocker versus angiotensin II receptor blocker in autosomal dominant polycystic kidney disease. Nephron Clin Pract 2005; 99: c18-c23.
93. Jafar TH, Stark PC, Schmid CH, et al. The effect of angiotensin-converting-enzyme inhibitors on progression of advanced polycystic kidney disease. Kidney Int 2005; 67: 265-271.
94. Ecder T, Edelstein CL, Chapman AB, et al. Reversal of left ventricular hypertrophy with angiotensin converting enzyme inhibition in hypertensive patients with autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 1999; 14: 1113-1116.
95. Schrier R, McFann K, Johnson A, et al. Cardiac and renal effects of standard versus rigorous blood pressure control in autosomal-dominant polycystic kidney disease: results of a seven-year prospective randomized study. J Am Soc Nephrol 2002; 13: 1733-1739.
96. Schrier RW, McFann KK, Johnson AM. Epidemiological study of kidney survival in autosomal dominant polycystic kidney disease. Kidney Int 2003; 63: 678-685.
97. Ecder T, Edelstein CL, Fick-Brosnahan GM, et al. Progress in the blood pressure control in autosomal dominant polycystic kidney disease. Am J Kidney Dis 2000; 36: 266-271.
98. Patch C, Charlton J, Roderick PJ, Gulliford MC. Use of antihypertensive medications and mortality of patients with autosomal dominant polycystic kidney disease: A population-based study. Am J Kidney Dis 2011; 57: 856-862.
99. Torres VE, Chapman AB, Perrone RD, et al. For the HALT PKD Study Group. Analysis of baseline parameters in the HALT polycystic kidney disease trials. Kidney Int 2012; 81: 577-585.
100. Schrier RW. Renal volume, renin-angiotensin-aldosterone system, hypertension and left ventricular hypertrophy in patients with autosomal dominant polycystic kidney disease. J Am Soc Nephrol 2009; 20: 1888-1893.
101. Ecder T, Schrier RW. Cardiovascular abnormalities in autosomal-dominant polycystic kidney disease. Nat Rev Nephrol 2009; 5: 221-228.
102. Gile RD, Cowley BD, Gattone VH, O'Donnell MP, Swan SK, Grantham JJ. Effect of lovastatin on the development of polycystic kidney disease in the Han:SPRD rat. Am J Kidney FDis 1995; 26: 501-507.
103. Zafar I, Tao Y, Falk S, McFann K, Schrier RW, Edelstein CL. Effect of statin and angiotensin-converting enzyme inhibition on structural and hemodynamic alterations in autosomal dominant polycystic kidney disease. Am J Physiol Renal Physiol 2007; 293: F854-F859.
104. van Dijk MA, Kamper AM, van Veen S, Souverijn JHM, Blauw GJ. Effect of simvastatin on renal function in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 2001; 16: 2152-2157.
105. Namli S, Oflaz H, Turgut F, et al. Improvement of endothelial dysfunction with simvastatin in patients with autosomal dominant polycystic kidney disease. Ren Fail 2007; 29: 55-59.
106. Cadnapaphornchai MA, George DM, Masoumi A, McFann K, Strain JD, Schrier RW. Effect of statin therapy on disease progression in pediatric ADPKD: Design and baseline characteristics of participants. Contemp Clin Trials 2011; 32: 437-445.
107. Wang Y, Chen X, Song Y, Caballero B, Cheskin LJ. Association between obesity and kidney disease: A systematic review and meta-analysis. Kidney Int 2008; 73: 19-33.
108. Henegar JR, Bigler SA, Henegar LK, et al. Functional and structural changes in the kidney in the early stages of obesity. J Am Soc Nephrol 2001; 12: 1211-1217.
109. Wolf G, Chen S, Han DC, Ziyadeh FN. Leptin and renal disease. Am J Kidney Dis 2002; 39: 1-11.
110. Wong H, Vivian L, Weiler G, Filler G. Patients with autosomal dominant polycystic kidney disease hyperfiltrate early in their disease. Am J Kidney Dis 2004; 43: 624-628.
111. Helal I, Reed B, McFann K, et al. Glomerular hyperfiltration and renal progression in children with autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 2011; 6: 2439-2443.
112. Orth SR, Hallan SI. Smoking: A risk factor for progression of chronic kidney disease and for cardiovascular morbidity and mortality in renal patients - Absence of evidence or evidence of absence? Clin J Am Soc Nephrol 2008; 3: 226-236.
113. Hallan SI, Orth SR. Smoking is a risk factor in the progression to kidney failure. Kidney Int 2011; 80: 516-523.